Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daclatasvir + asunaprevir + beclabuvir + sofosbuvir
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Daclatasvir + asunaprevir + beclabuvir + sofosbuvir is an experimental four-drug direct-acting antiviral (DAA) combination regimen evaluated by Bristol Myers Squibb for the treatment of chronic hepatitis C virus (HCV) infection, specifically genotype 1. The regimen, investigated in the Phase 2 FOURward study, combines four agents with distinct mechanisms of action: daclatasvir (an NS5A inhibitor), asunaprevir (an NS3 protease inhibitor), beclabuvir (a non-nucleoside NS5B polymerase inhibitor), and sofosbuvir (a nucleotide NS5B polymerase inhibitor). This 'quad therapy' was designed to explore whether a potent combination of multiple DAAs could achieve high sustained virologic response (SVR) rates with a significantly shortened treatment duration of 4 to 6 weeks in treatment-naive, non-cirrhotic patients, compared to the standard 12-week regimens.
- Brand names
- DaklinzaSunvepraSovaldi
- Other names
- FOURward regimenBMS Quad therapyDCV/ASV/BMS-791325 + sofosbuvir
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on daclatasvir + asunaprevir + beclabuvir + sofosbuvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daclatasvir + asunaprevir + beclabuvir + sofosbuvir.